Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of HBW-3220 versus investigator's choice in relapsed/refractory CLL/SLL after prior BTK inhibitor therapy
CTR20254795Phase 3Active
- Sponsor
- Hyperway Pharmaceutical
- Start
- Feb 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of HBW-3220 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Hyperway Pharmaceutical. Primary endpoint: Progression-free survival. Started Feb 2026; status: active.
02
Drugs
HBW-3220
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20254795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254795.